The Abernathy Group's II Clinical Investing Protocol®
The Food and Drug Administration has a rigorous process for testing and approving new drugs. The Abernathy Group II emulates this detailed approach with its Clinical Investing Protocol. Our painstakingly meticulous investment process strives to produce solid investments which are both low risk and uncorrelated to the market. This allows our co-investors to take confidence in knowing that decisions are being made with the best information from experts in both industry and finance.
To read full documentation on The Abernathy Group II process, view the 'Clinical Investing Protocol' PDF.